文献速递核素与放射性配体治疗放射性药物与辐射防护

经导管逆行注射非放射性DCFPyL竞争性阻断唾液腺摄取[18F]DCFPyL的临床前研究

Competitive blocking of salivary gland [18F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study.
PubMed 文献 · EJNMMI Res · 2021-07-21

该临床前研究在荷瘤小鼠中验证了经颌下腺逆行插管局部注射非放射性DCFPyL可选择性降低系统给药[18F]DCFPyL的唾液腺摄取而不影响肿瘤摄取。剂量探索队列显示局部阻断在0.1×和1×剂量水平使颌下腺摄取降低42-53%,全身给药组则呈剂量依赖性降低12-40%但伴肾脏摄取下降。合适剂量下该策略无毒性且不影响肿瘤摄取,有望减轻PSMA靶向放疗相关口干症。

要点

  • 经导管逆行局部注射DCFPyL可选择性降低唾液腺对[18F]DCFPyL的摄取。
  • 0.1×和1×剂量水平局部阻断使颌下腺摄取降低42-53%且不影响肿瘤摄取。
  • 全身给药阻断虽降低唾液腺摄取但伴肾脏摄取相应下降。

核心结论

  • 经唾液腺逆行灌注DCFPyL在合适剂量下可预测且选择性地降低系统给药[18F]DCFPyL的唾液腺摄取,同时不改变肿瘤摄取。

研究设计与样本

  • 临床前研究,先用心胸腺裸鼠剂量探索队列验证原理,后在22RV1荷瘤小鼠验证队列重复实验。
  • 颌下腺经插管局部阻断,DCFPyL剂量范围为放射性[18F]DCFPyL剂量的0.01×至1000×摩尔当量,10分钟后系统给药,1小时后处死行生物分布研究。
  • 毒性研究在高达1000×剂量下进行。

主要发现

  • 剂量探索队列中全身给药组颌下腺T/B和肾脏(肿瘤替代)呈剂量依赖性降低12-40%,0.01×时轻度阻断,1×时达最大阻断,至1000×无额外阻断。
  • 插管组在0.1×和1×剂量水平产生相似的42-53%降低,但无全身给药组所见的肾脏摄取相应下降。
  • 观察到DCFPyL从唾液腺向体循环「泄漏」的一些证据。
  • 22RV1荷瘤小鼠在0.1×和1×剂量水平的实验证实,合适阻断剂量下可选择性降低唾液腺摄取而不影响肿瘤摄取且无毒性。

关键数值与推荐

  • 局部阻断剂量0.1×和1×摩尔当量使颌下腺摄取降低42-53%。
  • 全身阻断剂量0.01×至1×使颌下腺T/B和肾脏摄取降低12-40%,1×达最大阻断。
  • 毒性研究剂量高达1000×。

临床怎么用

  • 该经导管逆行注射方法易于转化至临床,有望在不影响PSMA靶向放疗疗效的前提下减轻口干症。

局限性

  • 观察到DCFPyL从唾液腺向体循环泄漏的证据。
  • 研究为临床前小鼠实验,尚未在人体验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PSMA-targeted radionuclide therapy (TRT) is a promising treatment for prostate cancer (PCa), but dose-limiting xerostomia can severely limit its clinical adaptation, especially when using alpha-emitting radionuclides. With [18F]DCFPyL as a surrogate for PSMA-TRT, we report a novel method to selectively reduce salivary gland (SG) uptake of systemically administered [18F]DCFPyL by immediate prior infusion of non-radioactive standard of [18F]DCFPyL (DCFPyL) directly into the SG via retrograde cannulation. METHODS: A dose-finding cohort using athymic nude mice demonstrated proof of principle that SG uptake can be selectively blocked by DCFPyL administered either locally via cannulation (CAN group) or systemically (SYS group). The experiments were repeated in a validation cohort of 22RV1 tumor-bearing mice. Submandibular glands (SMG) of CAN mice were locally blocked with either saline or DCFPyL (dose range: 0.01× to 1000× molar equivalent of the radioactive [18F]DCFPyL dose). The radioactive dose of [18F]DCFPyL was administered systemically 10 min later and the mice euthanized after 1 h for biodistribution studies. Toxicity studies were done at up to 1000× dose. RESULTS: In the dose-finding cohort, the SYS group showed a dose-dependent 12-40% decrease in both the SMG T/B and the kidney (tumor surrogate). Mild blocking was observed at 0.01× , with maximal blocking reached at 1× with no additional blocking up to 1000× . In the CAN group, blocking at the 0.1× and 1× dose levels resulted in a similar 42-53% decrease, but without the corresponding decrease in kidney uptake as seen in the SYS group. Some evidence of "leakage" of DCFPyL from the salivary gland into the systemic circulation was observed. However, experiments in 22RV1 tumor-bearing mice at the 0.1× and 1× dose levels confirm that, at the appropriate blocking dose, SG uptake of [18F]DCFPyL can be selectively reduced without affecting tumor uptake and with no toxicity. CONCLUSION: Our results suggest that direct retrograde instillation of DCFPyL into the SG could predictably and selectively decrease salivary uptake of systemically administered [18F]DCFPyL without altering tumor uptake, if given at the appropriate dose. This novel approach is easily translatable to clinical practice and has the potential to mitigate xerostomia, without compromising the therapeutic efficacy of the PSMA-TRT.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Roy J, Warner BM, Basuli F, et al. Competitive blocking of salivary gland [18F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study. EJNMMI Res. 2021. PMID: 34287731. doi:10.1186/s13550-021-00803-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。